ACTRN12611000252910尚未招募3 期
Effect Of Extended Release Nicotinic Acid On Plasma Lipoprotein (a), Its Isoforms And Apo(a) Fragments.
A/Prof. K.Kostner0 个研究点目标入组 30 人开始时间: 2011年3月8日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- All
入选标准
- •Approximately 30 participants will be recruited for this study.
- •As per the protocol all participants will have elevated Lipoprotein (a), already be taking lipid lowering medication, and be either male or female between 18 and 75 years of age. It is expected that the ratio of recruitment will be unbalanced (male (60%) to female (40%) purely due to the incidence of disease in the community.
排除标准
- •Children are excluded for legal reasons and pregnant women are excluded due to safety considerations to the unborn.
研究者
相似试验
已完成
4 期
A study to investigate the effect of taking Nicotinic Acid Prolonged Release on abnormal artery blood vessel function in people with Type 2 diabetes who are on best-dose treatment with statin medications.ACTRN12606000466549Professor Gerald Watts50
已完成
3 期
The Slo-Niacin trial. A trial of phosphate lowering agent slo-Niacin in patients on haemodialysis.End stage renal failure.Chronic Kidney disease - mineral bone disorder.Hyperphosphataemia.Renal and Urogenital - Kidney diseaseMetabolic and Endocrine - Other metabolic disordersACTRN12611000500954Dr. Ken-Soon Tan33
进行中（未招募）
1 期
The effect of Niaspan (slow release nicotinic acid) on plasma phosphate, and renal phosphate handling in patents with severe chronic kidney disease - Niaspan in CKDChronic renal failure (CKD stages 4 &%)EUCTR2005-002982-35-GBBarts and The London NHS Trust
尚未招募
4 期
Abnormal serum triglyceride(form of fat)& low HDL cholesterol, important risk factors for heart & blood vessel diseases. Niacin, lipid lowering drug, is less used due to its side effects, can be minimized by adding Laropiprant. We study the drugs effect on both serum triglyceride & low HDL levelsCTRI/2011/08/001977Sub arm study of PURSE HIS funded by Department of Science and Technology Government of India50
进行中（未招募）
1 期
Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study) - NICOLaipoprotein (Lp)(a) has been associated with an increased risk of coronary heart disease, cerebrovascular disease, and peripheral arterial vascular disease. Potential therapies to reduce elevated Lp(a) levels include nicotinic acid (niacin), but there is a lack of randomised controlled studies assessing the effectiveness of these therapies in lowering Lp(a) as a primary endpoint and in reducing cardiovascular events in the long term.EUCTR2006-005710-12-DECharité Universitätsmedizin Berlin150